CN106955374B - 植入式器械 - Google Patents
植入式器械 Download PDFInfo
- Publication number
- CN106955374B CN106955374B CN201610016894.2A CN201610016894A CN106955374B CN 106955374 B CN106955374 B CN 106955374B CN 201610016894 A CN201610016894 A CN 201610016894A CN 106955374 B CN106955374 B CN 106955374B
- Authority
- CN
- China
- Prior art keywords
- acid
- implantable device
- zinc
- instrument matrix
- active medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011701 zinc Substances 0.000 claims abstract description 65
- 239000011159 matrix material Substances 0.000 claims abstract description 60
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 58
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000003814 drug Substances 0.000 claims abstract description 43
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940088529 claritin Drugs 0.000 claims abstract description 20
- 238000002513 implantation Methods 0.000 claims abstract description 12
- 239000007943 implant Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000011248 coating agent Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 20
- -1 sulfydryl Chemical group 0.000 claims description 20
- 239000008139 complexing agent Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 15
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 12
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229920006237 degradable polymer Polymers 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 229960003957 dexamethasone Drugs 0.000 claims description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 7
- 229960000890 hydrocortisone Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000178 monomer Substances 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 229960004584 methylprednisolone Drugs 0.000 claims description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 6
- 238000002464 physical blending Methods 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 229960001051 dimercaprol Drugs 0.000 claims description 5
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 5
- YXAOOTNFFAQIPZ-UHFFFAOYSA-N 1-nitrosonaphthalen-2-ol Chemical compound C1=CC=CC2=C(N=O)C(O)=CC=C21 YXAOOTNFFAQIPZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 4
- 229960003291 chlorphenamine Drugs 0.000 claims description 4
- 239000000174 gluconic acid Substances 0.000 claims description 4
- 235000012208 gluconic acid Nutrition 0.000 claims description 4
- 229960001144 mizolastine Drugs 0.000 claims description 4
- 229960003540 oxyquinoline Drugs 0.000 claims description 4
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 229920001083 polybutene Polymers 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 4
- 238000005204 segregation Methods 0.000 claims description 4
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 229940070710 valerate Drugs 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 3
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 239000005062 Polybutadiene Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 3
- 210000003445 biliary tract Anatomy 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 229920002857 polybutadiene Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 210000003437 trachea Anatomy 0.000 claims description 3
- 229960001124 trientine Drugs 0.000 claims description 3
- 210000003708 urethra Anatomy 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- YZQUECUNLLXRTM-UHFFFAOYSA-N 1-(pyridin-2-yldiazenyl)naphthalene-2-carbaldehyde Chemical compound O=CC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=N1 YZQUECUNLLXRTM-UHFFFAOYSA-N 0.000 claims description 2
- NBYLBWHHTUWMER-UHFFFAOYSA-N 2-Methylquinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(C)=CC=C21 NBYLBWHHTUWMER-UHFFFAOYSA-N 0.000 claims description 2
- OXBBIHZWNDPBMQ-UHFFFAOYSA-N 2-[2-(4-benzhydrylpiperazin-1-yl)ethoxy]ethanol Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 OXBBIHZWNDPBMQ-UHFFFAOYSA-N 0.000 claims description 2
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 claims description 2
- AXUZQJFHDNNPFG-LHAVAQOQSA-N 3-[(r)-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoic acid Chemical compound CN(C)C(=O)CCS[C@H](SCCC(O)=O)C1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 AXUZQJFHDNNPFG-LHAVAQOQSA-N 0.000 claims description 2
- HIOOFBBNJCVVJZ-UHFFFAOYSA-N 5-methyl-2-sulfanylbenzoic acid Chemical compound CC1=CC=C(S)C(C(O)=O)=C1 HIOOFBBNJCVVJZ-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- BQVIONBNDNFCCP-UHFFFAOYSA-N 6-butyl-4,10-dioxo-1,7-dihydro-1,7-phenanthroline-2,8-dicarboxylic acid Chemical compound N1C(C(O)=O)=CC(=O)C2=C1C(CCCC)=CC1=C2NC(C(O)=O)=CC1=O BQVIONBNDNFCCP-UHFFFAOYSA-N 0.000 claims description 2
- LGDFHDKSYGVKDC-UHFFFAOYSA-N 8-hydroxyquinoline-5-sulfonic acid Chemical compound C1=CN=C2C(O)=CC=C(S(O)(=O)=O)C2=C1 LGDFHDKSYGVKDC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004114 Ammonium polyphosphate Substances 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims description 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 2
- NFQIAEMCQGTTIR-UHFFFAOYSA-N Repirinast Chemical compound C12=CC=C(C)C(C)=C2NC(=O)C2=C1OC(C(=O)OCCC(C)C)=CC2=O NFQIAEMCQGTTIR-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 229960003792 acrivastine Drugs 0.000 claims description 2
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 235000019826 ammonium polyphosphate Nutrition 0.000 claims description 2
- 229920001276 ammonium polyphosphate Polymers 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 230000002590 anti-leukotriene effect Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 229950001468 bufrolin Drugs 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical class OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960002376 chymotrypsin Drugs 0.000 claims description 2
- 238000007334 copolymerization reaction Methods 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
- 229950002790 decloxizine Drugs 0.000 claims description 2
- 229960004073 deptropine Drugs 0.000 claims description 2
- ZWPODSUQWXAZNC-PMOLBWCYSA-N deptropine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2C1O[C@H](C1)C[C@H]2CC[C@@H]1N2C ZWPODSUQWXAZNC-PMOLBWCYSA-N 0.000 claims description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 2
- 229960005426 doxepin Drugs 0.000 claims description 2
- 229960001971 ebastine Drugs 0.000 claims description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 229950003420 efletirizine Drugs 0.000 claims description 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000325 emedastine Drugs 0.000 claims description 2
- 229960003449 epinastine Drugs 0.000 claims description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003592 fexofenadine Drugs 0.000 claims description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 229960004958 ketotifen Drugs 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960001474 meclozine Drugs 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229960000582 mepyramine Drugs 0.000 claims description 2
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims description 2
- 230000031990 negative regulation of inflammatory response Effects 0.000 claims description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical group OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004572 pizotifen Drugs 0.000 claims description 2
- 229920000141 poly(maleic anhydride) Polymers 0.000 claims description 2
- 108010064470 polyaspartate Proteins 0.000 claims description 2
- 229920002643 polyglutamic acid Polymers 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 2
- 150000004032 porphyrins Chemical class 0.000 claims description 2
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002244 promethazine hydrochloride Drugs 0.000 claims description 2
- 150000003214 pyranose derivatives Chemical class 0.000 claims description 2
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229940005657 pyrophosphoric acid Drugs 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 2
- 229960000620 ranitidine Drugs 0.000 claims description 2
- 229950009147 repirinast Drugs 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 235000011008 sodium phosphates Nutrition 0.000 claims description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 claims description 2
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 claims description 2
- 229950010302 tiaramide Drugs 0.000 claims description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 claims description 2
- 229960005342 tranilast Drugs 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229950003905 verlukast Drugs 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 claims 1
- WFNAKBGANONZEQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WFNAKBGANONZEQ-UHFFFAOYSA-N 0.000 claims 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 claims 1
- NAVWVHRQSDHCHD-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;potassium Chemical compound [K].OC(=O)CC(O)(C(O)=O)CC(O)=O NAVWVHRQSDHCHD-UHFFFAOYSA-N 0.000 claims 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229940120146 EDTMP Drugs 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 241000219000 Populus Species 0.000 claims 1
- VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 claims 1
- 229960000510 ammonia Drugs 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 229960004831 chlorcyclizine Drugs 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229930002875 chlorophyll Natural products 0.000 claims 1
- 235000019804 chlorophyll Nutrition 0.000 claims 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- ZTOGYGRJDIWKAQ-UHFFFAOYSA-N cyclohexene-1,2-diamine Chemical compound NC1=C(N)CCCC1 ZTOGYGRJDIWKAQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001140 cyproheptadine Drugs 0.000 claims 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims 1
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229940012017 ethylenediamine Drugs 0.000 claims 1
- 229960002259 nedocromil sodium Drugs 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 1
- 229960005332 zileuton Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 70
- 230000002792 vascular Effects 0.000 description 40
- 230000001575 pathological effect Effects 0.000 description 31
- 206010070834 Sensitisation Diseases 0.000 description 29
- 230000008313 sensitization Effects 0.000 description 29
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 22
- 210000004351 coronary vessel Anatomy 0.000 description 20
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 19
- 229910052742 iron Inorganic materials 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 238000005260 corrosion Methods 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 229910001297 Zn alloy Inorganic materials 0.000 description 6
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 230000007797 corrosion Effects 0.000 description 5
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 description 5
- 229960001508 levocetirizine Drugs 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 244000131522 Citrus pyriformis Species 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 229910045601 alloy Inorganic materials 0.000 description 4
- 239000000956 alloy Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000536 complexating effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 229950008885 polyglycolic acid Drugs 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000001548 drop coating Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- UEJVSOJRGUIWCY-UHFFFAOYSA-N 2-hydroxybenzoic acid;zinc Chemical compound [Zn].OC(=O)C1=CC=CC=C1O UEJVSOJRGUIWCY-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910000882 Ca alloy Inorganic materials 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- NITJMAGUTXQPTR-UHFFFAOYSA-N [Cu].[Ca].[Fe] Chemical compound [Cu].[Ca].[Fe] NITJMAGUTXQPTR-UHFFFAOYSA-N 0.000 description 1
- HRZMCMIZSOGQJT-UHFFFAOYSA-N [Zn].[Mn].[Mg] Chemical compound [Zn].[Mn].[Mg] HRZMCMIZSOGQJT-UHFFFAOYSA-N 0.000 description 1
- PEZHKZNKELGTPO-UHFFFAOYSA-N acetic acid ethane-1,2-diamine zinc Chemical compound [Zn].CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN PEZHKZNKELGTPO-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- QDOXWKRWXJOMAK-UHFFFAOYSA-N dichromium trioxide Chemical compound O=[Cr]O[Cr]=O QDOXWKRWXJOMAK-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- WDEABJKSGGRCQA-UHFFFAOYSA-N docebenone Chemical compound CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O WDEABJKSGGRCQA-UHFFFAOYSA-N 0.000 description 1
- 229950003667 docebenone Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- RSKQGBFMNPDPLR-UHFFFAOYSA-N niaprazine Chemical compound C=1C=CN=CC=1C(=O)NC(C)CCN(CC1)CCN1C1=CC=C(F)C=C1 RSKQGBFMNPDPLR-UHFFFAOYSA-N 0.000 description 1
- 229960002686 niaprazine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- MHTSJSRDFXZFHQ-UHFFFAOYSA-N quinoline-8-thiol Chemical compound C1=CN=C2C(S)=CC=CC2=C1 MHTSJSRDFXZFHQ-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002345 surface coating layer Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/84—Preparations for artificial teeth, for filling teeth or for capping teeth comprising metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/427—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of other specific inorganic materials not covered by A61L27/422 or A61L27/425
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/06—Zinc compounds
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C1/00—Making non-ferrous alloys
- C22C1/02—Making non-ferrous alloys by melting
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C18/00—Alloys based on zinc
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
- C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
- C22F1/16—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of other metals or alloys based thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/823—Stents, different from stent-grafts, adapted to cover an aneurysm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
- A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/045—Cobalt or cobalt alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Metallurgy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Thermal Sciences (AREA)
- Medical Informatics (AREA)
Abstract
本发明公开了一种植入式器械,包括器械基体和活性药物,所述器械基体为纯锌和/或锌合金,所述器械基体中锌的含量为0.1~100%,所述活性药物包括抗过敏药物。本发明的植入式器械被植入人体后,由于抗过敏药物的存在,植入物周围组织不会产生明显的致敏反应。本发明的植入式器械可以被用于植入体内支撑管腔,或填塞空腔器官组织,或作为骨科植入物等。
Description
技术领域
本发明属于医疗器械领域,涉及一种植入式器械。
背景技术
当前,植入式医疗器械通常采用金属及其合金、陶瓷、聚合物和相关复合材料制成。其中,金属材料基植入式医疗器械以其优越的力学性能,如高强度、高韧性等,尤为受到青睐。
目前,在心血管植入应用领域,血管支架一般采用不可降解的金属制成,其缺点是金属不可降解、无法取出,滞留在血管内容易引发晚期血栓等诸多晚期不良事件。因此,使用锌、铁等可腐蚀降解的金属材料制备的植入式医疗器械,具备良好的应用潜力。以锌作为基体材料的可吸收支架具有良好的柔顺性和生物相容性,且锌离子还有抗氧化、稳定内皮的作用,同时由于锌离子在人体组织中的运输非常迅速,因此锌基植入式器械附近不会出现锌富集、细胞毒性或坏死。
锌也可以应用于骨科植入式器械领域。由于锌离子可以激活成骨细胞中的氨酰tRNA合成酶,并可有效抑制破骨细胞的分化与生长,因此锌离子的存在不仅促进了骨钙盐含量的增加,还有利于骨胶原蛋白含量的提高,说明锌离子有直接的促成骨组织生长功能。另外,锌离子还可以促进软骨低聚基质蛋白与胶原的结合,是软骨成长与再生的催化元素。一枚锌基可降解骨钉每天释放的锌大约为0.2~0.3毫克,而成年人每天摄入大约300毫克锌才可能会有一定毒性反应。可见锌基可降解骨科植入式器械降解释放的锌离子不会引起全身毒性。
植入式器械不仅需要具有良好的生物相容性和低毒性或无毒性,还需要满足临床上的安全性要求。对于含锌植入式器械,业界长期以来一直希望能降低锌植入后早期的安全性风险,但一直均未能成功解决此问题。
发明内容
含锌植入式器械植入后在早期可能会导致局部组织的致敏性反应,例如,含锌的血管支架在植入血管后可能会引发周围血管组织的致敏性反应,进而导致支架阻塞甚或更严重的死亡风险,从而可能具有严重的安全隐患。我们认为,该早期致敏性反应由纯锌或锌合金自身在体内腐蚀产生的游离锌离子引起。本发明的目的在于降低含锌植入式器械的前述安全性风险。本发明的植入式器械可以被用于植入体内支撑管腔(例如血管支架),或填塞空腔器官组织(如封堵器),或作为骨科植入物等。
本发明的技术方案如下:
本发明提供一种植入式器械,包括器械基体和活性药物,所述器械基体为纯锌和/或锌合金,所述器械基体中锌的含量为0.1~100%,所述活性药物包括抗过敏药物。所述锌合金为医用锌基合金,其由锌与人体内营养元素或低毒元素组成。所述人体内营养元素或低毒元素选自以下元素中的至少一种:铁、镁、钙、钠、铜、锰、铬、硒、钼、钴、镍、钒、锡、硅、锶、硼、铈、锂、钾。
在其中一个实施例中,所述植入式器械还包括锌络合剂,所述锌络合剂与所述器械基体中的纯锌或锌合金在体液中形成络合物。络合剂又称为配体,结构上含有能提供孤对电子或π电子的配位基团。所述锌络合剂可以在纯锌和/或锌合金腐蚀的过程中与腐蚀产物二价锌离子发生络合反应,减少游离锌离子的数量,从而使植入物周围组织不发生明显的致敏反应。
在其中一个实施例中,所述锌络合剂含有至少1个配位基团;所述配位基团选自稠环芳烃上的羟基、巯基、胺基、芳杂环基团、亚硝基、羰基、磺基,磷酸基团或有机膦基团中的至少一种;所述稠环芳烃上的羟基选自酚羟基;所述芳杂环基团选自呋喃基、吡咯基、咪唑基、三唑基、噻吩基、噻唑基、吡啶基、吡啶酮基、吡喃基、吡喃酮基、嘧啶基、哒嗪基、吡嗪基、喹啉基、异喹啉基、酞嗪基、喋啶基、吲哚基、嘌呤基或菲咯啉基中的至少一种。
在其中一个实施例中,所述锌络合剂选自以下至少一种:含稠环芳烃上的羟基的多齿配体,包括8-羟基喹啉、8-羟基喹哪啶、4,5-二羟基苯-1,3-二磺酸钠、4-[3,5-二-羟苯基-1H-1,2,4-三唑]-苯甲酸、1-(2-吡啶偶氮)-2-萘酚;所述含巯基的络合剂,包括8-巯基喹啉、巯基乙酸、二巯基丙醇、5-甲基-2-巯基苯甲酸甲酯;含胺基的络合剂,包括乙二胺、三乙烯四胺、乙二胺四乙酸、乙二胺四乙酸四钠、三亚乙基四胺、N-(2-羟乙基)乙二胺-N,N’,N’-三乙酸或N'-[5-[[4-[[5-(乙酰羟胺基)戊基]氨]-1,4-二氧丁基]羟胺]戊基]-N-(5-氨基戊基)-N-羟基琥珀酰胺;含芳杂环基团的络合剂,包括邻菲罗啉、联吡啶、卟啉、卟吩、叶绿素、血红蛋白或1,2-二甲基-3-羟基-4-吡啶酮;含亚硝基的多齿配体,包括1-亚硝基-2-萘酚或1-亚硝基-2-萘酚-6-磺酸钠;含磺基的多齿配体,包括磺基水杨酸或8-羟基喹啉-5-磺酸;含磷酸基团的多齿配体,包括焦磷酸、三聚磷酸、六偏聚磷酸、多聚磷酸、焦磷酸钠、六偏聚磷酸钠或多聚磷酸铵;含有机膦的络合剂,包括二乙烯三胺五甲叉膦酸钾或乙二胺四甲叉膦酸钠;含羰基的配体,包括羧酸及其盐、酸酐、酯、酰胺、聚羧酸或聚酸酐;进一步地,所述含羰基的配体,包括葡萄糖酸、草酸、酒石酸、苹果酸、草酰乙酸、延胡索酸、马来酸、柠檬酸、氨三乙酸、二乙烯三胺五羧酸、海藻酸、谷氨酸、天冬氨酸、鸟氨酸、赖氨酸、1,2-二氨基环己烷-N,N,N’,N’-四乙酸、柠檬酸钾、柠檬酸钙、柠檬酸甘油酯、乙酰水杨酸、磺基水杨酰胺、聚天冬氨酸、聚谷氨酸、聚鸟氨酸、聚赖氨酸或聚马来酸酐。
在其中一个实施例中,所述抗过敏药物选自抗组胺类抗过敏药物、抗白三烯药物、肥大细胞膜稳定剂、糖皮质激素类抗过敏药物或调节免疫类抗过敏药物中的至少一种。
在其中一个实施例中,所述抗过敏药物选自氯苯吡胺、苯海拉明、盐酸异丙嗪、西替利嗪、氯雷他定、咪唑斯汀、依巴斯汀、阿司咪唑、特非那定、地氯雷他定、非索非那定、赛庚啶、酮替芬、左旋西替利嗪、氯苯甲嗪、乙氟利嗪、卡依巴斯丁、氮卓斯汀、去氯羟嗪、氯环利嗪、氨来仙司、阿伐斯丁、阿扎他丁、甲喹吩嗪、左卡斯汀、赛他斯丁、斯喹那定、地普托品、苯噻啶、吡拉明、雷尼替丁、依美斯汀、依匹斯汀、异丙嗪、孟鲁司特、扎鲁司特、托卡司特、齐留通、氨来洛斯、伊布拉特、泊米司特、多塞平、维鲁司特、多西苯醌、色甘酸钠、色羟丙钠、尼多考米钠、曲尼司特、噻拉米特、瑞吡司特、丁氮菲酸、苯氮嘌呤酮、塔赞司特、奥萨格雷、瑞吡司特、地塞米松、甲基强的松龙、氢化可的松、曲安奈德、皮质类固醇、维他命C、钙剂、辅酶Q10或糜胰蛋白酶中的至少一种。
在其中一个实施例中,所述抗过敏药物在所述器械基体表面的含量范围为10~500ug/cm2,进一步地,为100~300ug/cm2。
在其中一个实施例中,所述活性药物还包括抗再狭窄药物、抗增生药物、抗血小板药物或抗炎症反应药物中的至少一种。
在其中一个实施例中,所述活性药物与所述器械基体接触的方式选自以下至少一种:所述活性药物至少部分覆盖在所述器械基体的表面;或者所述器械基体具有微孔,所述活性药物设于所述器械基体的微孔中;或者所述器械基体设有缝隙、孔隙或凹槽,所述活性药物设于所述器械基体的缝隙、孔隙或凹槽中;或者所述器械基体具有内腔,所述活性药物填充在所述器械基体的所述内腔中。
在其中一个实施例中,所述活性药物以涂层的形式存在。所述涂层的厚度范围为2~50μm,进一步地,为5~25μm。
在其中一个实施例中,所述涂层中还包括聚合物载体。所述聚合物载体为可降解的聚合物,所述可降解的聚合物由聚乳酸、聚乙醇酸、聚丁二酸酯、聚(β-羟基丁酸酯)、聚已内酯、聚己二酸乙二醇酯、聚乳酸-乙醇酸共聚物或聚戊酸酯中的一种或者几种物理共混而成,或者由聚乳酸、聚乙醇酸、聚丁二酸酯、聚(β-羟基丁酸酯)、聚已内酯、聚己二酸乙二醇酯、聚乳酸-乙醇酸共聚物或聚戊酸酯中的一种或者几种共聚而成,或者所述聚合物载体为不可降解的聚合物,所述不可降解的聚合物由聚氨酯、聚碳酸酯、聚甲基丙烯酸甲酯、聚苯乙烯、聚丁烯或聚甲基丙烯酸丁酯中的一种或者几种物理共混而成,或者由聚氨酯、聚碳酸酯、聚甲基丙烯酸甲酯、聚苯乙烯、聚丁烯或聚甲基丙烯酸丁酯中的一种或者几种共聚而成,或者所述聚合物载体由所述可降解的聚合物的单体和所述不可降解的聚合物的单体中的一种或者几种物理共混而成,或者由所述可降解的聚合物的单体和所述不可降解的聚合物的单体中的一种或者几种共聚而成。
在其中一个实施例中,所述聚合物载体与所述活性药物的质量比为50:1~1:20,进一步地,为10:1~1:10。
在其中一个实施例中,所述植入式器械为支架、封堵器、骨科植入物、齿科植入物、缝合线或螺栓。
在其中一个实施例中,所述支架为血管支架、气管支架、食道支架、尿道支架、肠道支架或胆道支架。
在其中一个实施例中,所述骨科植入物为固定螺钉、固定铆钉或骨板。
当本发明提供的植入式器械中包括锌络合剂,但不包括活性药物时,该植入式器械仍可表现出对周围组织的低致敏风险,说明锌络合剂也可降低锌对组织的致敏作用。
本发明与现有技术相比,具有以下有点和有益效果:
本发明的植入式器械,属于业界首次发现纯锌或锌合金会因自身腐蚀致敏,并属于首次利用抗过敏药物来抑制含纯锌或锌合金的植入式器械在植入人体后因纯锌或锌合金自身腐蚀导致的致敏作用,降低了植入物的安全隐患,解决了业内长期以来渴望解决但始终一直未能成功的含锌植入器械表现出的组织致敏性风险这一技术难题。
附图说明
图1为对比例1的血管支架植入猪冠脉血管6个月后,支架周围组织的致敏性病理切片;
图2为对比例2的血管支架植入猪冠脉血管6个月后,支架周围组织的致敏性病理切片;
图3为实施例1的血管支架植入猪冠脉血管6个月后,支架周围组织的病理切片;
图4为实施例2的血管支架植入猪冠脉血管6个月后,支架周围组织的病理切片;
图5为实施例3的血管支架植入猪冠脉血管1个月后,支架周围组织的病理切片;
图6为实施例4的血管支架植入猪冠脉血管3个月后,支架周围组织的病理切片;
图7为实施例5的血管支架植入猪冠脉血管6个月后,支架周围组织的病理切片;
图8为实施例6的血管支架植入猪冠脉血管6个月后,支架周围组织的病理切片;
图9为实施例7的血管支架植入猪冠脉血管1个月后,支架周围组织的病理切片;
图10为实施例8的血管支架植入猪冠脉血管3个月后,支架周围组织的病理切片;
图11为实施例9的血管支架植入猪冠脉血管6个月后,支架周围组织的病理切片。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文在说明书中所使用的术语只是为了描述具体的实施例的目的,不是旨在于限制本发明。
对比例1
将一种以纯锌为基体的血管支架,其器械基体中锌的含量为100%,植入猪冠脉血管。6个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图1,病理切片显示,对比例1的血管支架周围的血管组织生成大量嗜酸性粒细胞。即,本对比例的纯锌基血管支架对植入组织具有明显的致敏性。
对比例2
将一种以铁锌合金为基体的血管支架,其器械基体中锌的含量为70%,铁含量为25%,镁含量为3.5%,钙含量为0.5%,铜含量为0.2%,其余为夹杂元素,植入猪冠脉血管。6个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图2,病理切片显示,对比例2的血管支架周围的血管组织生成大量嗜酸性粒细胞。即,本对比例的铁锌合金血管支架对植入组织具有明显的致敏性。
实施例1
一种以铁锌合金为基体的血管支架,其器械基体中锌含量为95%,铁含量为4.5%,除锌、铁以外的夹杂元素总量为0.5%。向所述支架的表面滴涂含有聚乳酸、地塞米松和葡萄糖酸的混合物,干燥后得到实施例1的血管支架,支架表面涂层厚度为2μm,涂层中聚乳酸和地塞米松的质量比为2:1,地塞米松药物在器械基体表面的含量为100ug/cm2。将本实施例的血管支架植入猪冠脉血管。6个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图3,病理切片显示,本实施例的血管支架周围的血管组织没有产生嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有致敏性。
本实施例的血管支架含有抗过敏药物地塞米松及可以与锌生成络合物的葡萄糖酸,当其被植入血管组织后,地塞米松的药效抑制了血管支架器械基体中的锌合金对血管组织的致敏作用。另外,葡萄糖酸与铁锌合金的腐蚀产物——锌离子络合,减少了游离锌离子的数量,进一步降低了植入物的致敏风险。
实施例2
将一种以纯锌为基体的支架,其器械基体中锌含量为99.95%,其余为夹杂元素,表面浸涂于含有聚乙醇酸、甲基强的松龙、乙二胺四乙酸四钠盐以及雷帕霉素的混合物中,混合物中三者的质量比为50:1:1,得到厚度为25μm的涂层,干燥后即可得到实施例2的血管支架,甲基强的松龙药物在器械基体表面的含量为200ug/cm2。将本实施例的血管支架植入猪冠脉血管。6个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图4,病理切片显示,本实施例的血管支架周围的血管组织没有产生嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有致敏性。
本实施例的血管支架含有抗过敏药物甲基强的松龙及可以与锌生成络合物的乙二胺四乙酸,当其被植入血管组织后,甲基强的松龙的药效抑制了血管支架器械基体中的纯锌对血管组织的致敏作用。另外,乙二胺四乙酸四钠盐与器械基体的腐蚀产物——锌离子络合,减少了游离锌离子的数量,进一步降低了植入物的致敏风险。
实施例3
一种表面镀锌的铁基支架,其器械基体中锌含量为1%,铁含量为98%,其余为夹杂元素。先在器械基体表面喷涂含有聚乳酸乙醇酸、氢化可的松和乙酰水杨酸的溶液,得到厚度为50μm的涂层,涂层中聚乳酸乙醇酸和氢化可的松的质量比为1:5,然后在药物涂层表面再次涂覆厚度为5μm的聚乳酸涂层,即得到实施例3的血管支架,氢化可的松药物在器械基体表面的含量为300ug/cm2。将本实施例的血管支架植入猪冠脉血管。1个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图5,病理切片显示,本实施例的血管支架周围的血管组织没有产生嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有致敏性。
本实施例的血管支架含有抗过敏药物氢化可的松及可以与锌生成络合物的乙酰水杨酸,当其被植入血管组织后,氢化可的松的药效抑制了血管支架器械基体中的纯锌对血管组织的致敏作用。另外,乙酰水杨酸与锌离子络合,减少了游离锌离子的数量,进一步降低了植入物的致敏风险。
实施例4
一种表面有凹槽的血管支架,其器械基体为含有锌、镁和铁的合金,器械基体中锌含量为40%,铁含量为50%,镁含量为9.5%,其余为夹杂元素。向所述支架的外表面及凹槽里滴涂含有聚苯乙烯、8‐羟基喹啉和左西替利嗪的混合物,得到厚度为25μm的涂层,涂层中聚苯乙烯和左西替利嗪的质量比为1:1,即可得到实施例4的血管支架,左西替利嗪药物在器械基体表面的平均含量为50ug/cm2。将本实施例的血管支架植入猪冠脉血管。3个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图6,病理切片显示,本实施例的血管支架周围的血管组织没有产生嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有致敏性。
本实施例的血管支架含有抗过敏药物左西替利嗪及可以与锌生成络合物的8-羟基喹啉,当其被植入血管组织后,左西替利嗪的药效抑制了血管支架器械基体中的锌合金对血管组织的致敏作用。另外,8-羟基喹啉与锌离子络合,减少了游离锌离子的数量,进一步降低了植入物的致敏风险。
实施例5
一种锌锰镁合金的血管支架,其器械基体中锌含量为20%,锰含量为5%,镁含量为75%,该支架表面分布多个缝隙,向所述缝隙中填塞地塞米松,得到实施例5的血管支架,地塞米松药物在器械基体表面的含量为500ug/cm2。将本实施例的血管支架植入猪冠脉血管。6个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图7,病理切片显示,本实施例的血管支架周围的血管组织没有产生明显的嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有明显的致敏性。
实施例6
一种表面镀锌的铁铜钙合金支架,其器械基体中铁含量为97%,铜含量为1%,钙含量为0.5%,锌含量为0.5%,其余为夹杂元素。将该支架表面浸涂于含有聚碳酸酯和氯苯吡胺的混合物中,得到厚度为5μm的涂层,涂层中聚碳酸酯和氯苯吡胺的质量比为1:20,即可得到实施例6的血管支架,氯苯吡胺药物在器械基体表面的含量为150ug/cm2。将本实施例的血管支架植入猪冠脉血管。6个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图8,病理切片显示,本实施例的血管支架周围的血管组织仅生成个别嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有明显的致敏性。
实施例7
一种以纯锌为基体的支架,其器械基体中锌含量为100%,在支架的部分表面刷涂含有聚乙醇酸、咪唑斯汀以及紫杉醇的混合物,得到厚度为30μm的涂层,涂层中三者的质量比为1:10:1,即可得到实施例7的血管支架,咪唑斯汀药物在器械基体表面的含量为10ug/cm2。将本实施例的血管支架植入猪冠脉血管。1个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图9,病理切片显示,本实施例的血管支架周围的血管组织没有生成明显的嗜酸性粒细胞,即,本实施例的血管支架对植入组织没有明显的致敏性。
实施例8
一种铁锌合金支架,其器械基体中铁含量为99.9%,锌含量为0.1%。向该支架的表面涂覆二巯基丙醇并干燥,即可得到实施例8的血管支架。将本实施例的血管支架植入猪冠脉血管。3个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图10,病理切片显示,本实施例的血管支架周围的血管组织没有生成明显的嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有明显的致敏性。
本实施例的血管支架包括可以与锌离子生成络合物的二巯基丙醇,当其被植入血管组织后,二巯基丙醇与锌合金的腐蚀产物——锌离子络合,降低了游离锌离子的浓度,植入物周围组织没有产生明显的致敏反应。
实施例9
一种以纯锌为基体的支架,其器械基体中锌含量为100%。将该支架的外表面在柠檬酸三钠中辊压,得到实施例9的血管支架,其表面为不连续的柠檬酸涂层,涂层平均厚度为10μm。将本实施例的血管支架植入猪冠脉血管。6个月后,取出支架及其所在的血管组织,对血管组织进行病理观察。
请参阅图11,病理切片显示,本实施例的血管支架周围的血管组织没有生成明显的嗜酸性粒细胞。即,本实施例的血管支架对植入组织没有明显的致敏性。
本实施例的血管支架包括可以与锌离子生成络合物的柠檬酸三钠,当其被植入血管组织后,柠檬酸三钠与锌合金的腐蚀产物——锌离子络合,降低了游离锌离子的浓度,植入物周围组织没有产生明显的致敏反应。
在实施例1至9中,仅以含锌的血管支架对本发明的具体实施方式作了示意性说明,本发明提供的技术方案也可以用于其它植入式器械,例如支架、封堵器、骨科植入物、齿科植入物、缝合线或螺栓。所述支架为血管支架、气管支架、食道支架、尿道支架、肠道支架或胆道支架。所述骨科植入物为固定螺钉、固定铆钉或骨板。
以上结合附图对本发明的实施例进行了描述,但是本发明并不局限于上述的具体实施方式,上述的具体实施方式仅仅是示意性的,而不是限制性的,本领域的普通技术人员在本发明的启示下,在不脱离本发明宗旨和权利要求所保护的范围情况下,还可做出很多形式,这些均属于本发明的保护之内。
Claims (16)
1.一种植入式器械,包括器械基体和活性药物,其特征在于,所述器械基体为纯锌和/或锌合金,所述器械基体中锌的含量为0.1~100%,所述活性药物包括抗过敏药物,所述植入式器械还包括锌络合剂,所述锌络合剂与所述器械基体中的纯锌或锌合金在体液中形成络合物。
2.根据权利要求1所述的植入式器械,其特征在于,所述锌络合剂含有至少1个配位基团;所述配位基团选自稠环芳烃上的羟基、巯基、胺基、芳杂环基团、亚硝基、羰基、磺基,磷酸基团或有机膦基团中的至少一种;所述稠环芳烃上的羟基选自酚羟基;所述芳杂环基团选自呋喃基、吡咯基、咪唑基、三唑基、噻吩基、噻唑基、吡啶基、吡啶酮基、吡喃基、吡喃酮基、嘧啶基、哒嗪基、吡嗪基、喹啉基、异喹啉基、酞嗪基、喋啶基、吲哚基、嘌呤基或菲咯啉基中的至少一种。
3.根据权利要求2所述的植入式器械,其特征在于,所述锌络合剂选自以下至少一种:含稠环芳烃上的羟基的多齿配体,包括8-羟基喹啉、8-羟基喹哪啶、4,5-二羟基苯-1,3-二磺酸钠、4-[3,5-二-羟苯基-1H-1,2,4-三唑]-苯甲酸、1-(2-吡啶偶氮)-2-萘酚;含巯基的络合剂,包括8-巯基喹啉、巯基乙酸、二巯基丙醇、5-甲基-2-巯基苯甲酸甲酯;含胺基的络合剂,包括乙二胺、三乙烯四胺、乙二胺四乙酸、乙二胺四乙酸四钠、三亚乙基四胺、N-(2-羟乙基)乙二胺-N,N’,N’-三乙酸或N'-[5-[[4-[[5-(乙酰羟胺基)戊基]氨]-1,4-二氧丁基]羟胺]戊基]-N-(5-氨基戊基)-N-羟基琥珀酰胺;含芳杂环基团的络合剂,包括邻菲罗啉、联吡啶、卟啉、卟吩、叶绿素、血红蛋白或1,2-二甲基-3-羟基-4-吡啶酮;含亚硝基的多齿配体,包括1-亚硝基-2-萘酚或1-亚硝基-2-萘酚-6-磺酸钠;含磺基的多齿配体,包括磺基水杨酸或8-羟基喹啉-5-磺酸;含磷酸基团的多齿配体,包括焦磷酸、三聚磷酸、六偏聚磷酸、多聚磷酸、焦磷酸钠、六偏聚磷酸钠或多聚磷酸铵;含有机膦的络合剂,包括二乙烯三胺五甲叉膦酸钾或乙二胺四甲叉膦酸钠;含羰基的配体,包括羧酸及其盐、酸酐、酯、酰胺、聚羧酸或聚酸酐。
4.根据权利要求3所述的植入式器械,其特征在于,所述含羰基的配体,包括葡萄糖酸、草酸、酒石酸、苹果酸、草酰乙酸、延胡索酸、马来酸、柠檬酸、氨三乙酸、二乙烯三胺五羧酸、海藻酸、谷氨酸、天冬氨酸、鸟氨酸、赖氨酸、1,2-二氨基环己烷-N,N,N’,N’-四乙酸、柠檬酸钾、柠檬酸钙、柠檬酸甘油酯、乙酰水杨酸、磺基水杨酰胺、聚天冬氨酸、聚谷氨酸、聚鸟氨酸、聚赖氨酸或聚马来酸酐。
5.根据权利要求1所述的植入式器械,其特征在于,所述抗过敏药物选自抗组胺类抗过敏药物、抗白三烯药物、肥大细胞膜稳定剂、糖皮质激素类抗过敏药物或调节免疫类抗过敏药物中的至少一种。
6.根据权利要求5所述的植入式器械,其特征在于,所述抗过敏药物选自氯苯吡胺、苯海拉明、盐酸异丙嗪、西替利嗪、氯雷他定、咪唑斯汀、依巴斯汀、阿司咪唑、特非那定、地氯雷他定、非索非那定、赛庚啶、酮替芬、左旋西替利嗪、氯苯甲嗪、乙氟利嗪、卡依巴斯丁、氮卓斯汀、去氯羟嗪、氯环利嗪、氨来仙司、阿伐斯丁、阿扎他丁、甲喹吩嗪、左卡斯汀、赛他斯丁、斯喹那定、地普托品、苯噻啶、吡拉明、雷尼替丁、依美斯汀、依匹斯汀、异丙嗪、孟鲁司特、扎鲁司特、托卡司特、齐留通、氨来洛斯、伊布拉特、泊米司特、多塞平、维鲁司特、多西苯醌、色甘酸钠、色羟丙钠、尼多考米钠、曲尼司特、噻拉米特、瑞吡司特、丁氮菲酸、苯氮嘌呤酮、塔赞司特、奥萨格雷、地塞米松、甲基强的松龙、氢化可的松、曲安奈德、皮质类固醇、维他命C、钙剂、辅酶Q10或糜胰蛋白酶中的至少一种。
7.根据权利要求1所述的植入式器械,其特征在于,所述抗过敏药物在所述器械基体表面的含量范围为10~500ug/cm2。
8.根据权利要求7所述的植入式器械,其特征在于,所述抗过敏药物在所述器械基体表面的含量范围为100~300ug/cm2。
9.根据权利要求1所述的植入式器械,其特征在于,所述活性药物还包括抗再狭窄药物、抗增生药物、抗血小板药物或抗炎症反应药物中的至少一种。
10.根据权利要求1所述的植入式器械,其特征在于,所述活性药物与所述器械基体接触的方式选自以下至少一种:所述活性药物至少部分覆盖在所述器械基体的表面;或者所述器械基体具有微孔,所述活性药物设于所述器械基体的微孔中;或者所述器械基体设有缝隙、孔隙或凹槽,所述活性药物设于所述器械基体的缝隙、孔隙或凹槽中;或者所述器械基体具有内腔,所述活性药物填充在所述器械基体的所述内腔中。
11.根据权利要求10所述的植入式器械,其特征在于,所述活性药物以涂层的形式存在,所述涂层的厚度范围为2~50μm。
12.根据权利要求11所述的植入式器械,其特征在于,所述涂层的厚度范围为5~25μm。
13.根据权利要求11所述的植入式器械,其特征在于,所述涂层中还包括聚合物载体,所述聚合物载体为可降解的聚合物,所述可降解的聚合物由聚乳酸、聚乙醇酸、聚丁二酸酯、聚(β-羟基丁酸酯)、聚已内酯、聚己二酸乙二醇酯、聚乳酸-乙醇酸共聚物或聚戊酸酯中的一种或者几种物理共混而成,或者由聚乳酸、聚乙醇酸、聚丁二酸酯、聚(β-羟基丁酸酯)、聚已内酯、聚己二酸乙二醇酯、聚乳酸-乙醇酸共聚物或聚戊酸酯中的一种或者几种共聚而成,或者所述聚合物载体为不可降解的聚合物,所述不可降解的聚合物由聚氨酯、聚碳酸酯、聚甲基丙烯酸甲酯、聚苯乙烯、聚丁烯或聚甲基丙烯酸丁酯中的一种或者几种物理共混而成,或者由聚氨酯、聚碳酸酯、聚甲基丙烯酸甲酯、聚苯乙烯、聚丁烯或聚甲基丙烯酸丁酯中的一种或者几种共聚而成,或者所述聚合物载体由所述可降解的聚合物的单体和所述不可降解的聚合物的单体中的一种或者几种物理共混而成,或者由所述可降解的聚合物的单体和所述不可降解的聚合物的单体中的一种或者几种共聚而成。
14.根据权利要求13所述的植入式器械,其特征在于,所述聚合物载体与所述活性药物的质量比为50:1~1:20。
15.根据权利要求14所述的植入式器械,其特征在于,所述聚合物载体与所述活性药物的质量比为10:1~1:10。
16.根据权利要求1所述的植入式器械,其特征在于,所述植入式器械选自支架、封堵器、骨科植入物、齿科植入物、缝合线或螺栓,其中,所述支架选自血管支架、气管支架、食道支架、尿道支架、肠道支架或胆道支架,所述骨科植入物选自固定螺钉、固定铆钉或骨板。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610016894.2A CN106955374B (zh) | 2016-01-08 | 2016-01-08 | 植入式器械 |
PCT/CN2016/087291 WO2017117922A1 (zh) | 2016-01-08 | 2016-06-27 | 植入式器械 |
EP16883063.6A EP3400969B1 (en) | 2016-01-08 | 2016-06-27 | Implanted device |
US16/068,122 US10799612B2 (en) | 2016-01-08 | 2016-06-27 | Implanted device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610016894.2A CN106955374B (zh) | 2016-01-08 | 2016-01-08 | 植入式器械 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106955374A CN106955374A (zh) | 2017-07-18 |
CN106955374B true CN106955374B (zh) | 2019-11-08 |
Family
ID=59273140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610016894.2A Active CN106955374B (zh) | 2016-01-08 | 2016-01-08 | 植入式器械 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10799612B2 (zh) |
EP (1) | EP3400969B1 (zh) |
CN (1) | CN106955374B (zh) |
WO (1) | WO2017117922A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109381751B (zh) * | 2017-08-08 | 2022-01-28 | 上海微创医疗器械(集团)有限公司 | 一种可降解金属支架及其制备方法 |
CN109589456B (zh) * | 2017-09-30 | 2024-03-19 | 元心科技(深圳)有限公司 | 植入式器械 |
CN109966563B (zh) * | 2017-12-28 | 2021-08-03 | 元心科技(深圳)有限公司 | 植入式载药器械 |
CN108273119B (zh) * | 2018-03-08 | 2020-11-20 | 戴庆涛 | 一种胃肠外科的手术缝合线及其制作方法 |
GB2575487B (en) * | 2018-07-12 | 2023-02-08 | Cook Medical Technologies Llc | Coated medical device and method of coating such a device |
CN111359021A (zh) * | 2018-12-25 | 2020-07-03 | 先健科技(深圳)有限公司 | 含锌植入器械 |
CN111110414B (zh) * | 2019-12-06 | 2022-01-04 | 先健科技(深圳)有限公司 | 植入系统 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090093875A1 (en) * | 2007-05-01 | 2009-04-09 | Abbott Laboratories | Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations |
CA2502018A1 (en) * | 2004-04-16 | 2005-10-16 | Conor Medsystems, Inc. | Bioresorbable stent delivery system |
US8293261B2 (en) * | 2005-01-28 | 2012-10-23 | Terumo Kabushiki Kaisha | Intravascular implant |
CA2885981A1 (en) * | 2005-04-05 | 2006-10-12 | Elixir Medical Corporation | Degradable implantable medical devices |
US20070244548A1 (en) * | 2006-02-27 | 2007-10-18 | Cook Incorporated | Sugar-and drug-coated medical device |
CN101077862B (zh) | 2006-05-26 | 2011-04-20 | 首都医科大学 | D-葡萄糖基-l-氨基酸、其制备方法和应用 |
AU2008206954A1 (en) * | 2007-01-19 | 2008-07-24 | Cinvention Ag | Partially bioabsorbable implant |
RU2452517C2 (ru) * | 2007-01-30 | 2012-06-10 | Хемотек Аг | Биоразрушаемое средство для поддержания просвета сосудов |
WO2008122596A2 (en) | 2007-04-05 | 2008-10-16 | Cinvention Ag | Curable therapeutic implant composition |
US8084077B2 (en) * | 2007-05-25 | 2011-12-27 | Abbott Laboratories | One-step phosphorylcholine-linked polymer coating and drug loading of stent |
US8172908B2 (en) * | 2008-01-17 | 2012-05-08 | The University Of Hong Kong | Implant for tissue engineering |
CN101283922A (zh) * | 2008-05-21 | 2008-10-15 | 中国科学院金属研究所 | 生物活性可吸收骨内固定植入器械 |
CN101283992A (zh) | 2008-05-29 | 2008-10-15 | 胡传良 | 盐酸曲美他嗪分散片及其制备方法 |
US9283305B2 (en) | 2009-07-09 | 2016-03-15 | Medtronic Vascular, Inc. | Hollow tubular drug eluting medical devices |
CN102190591A (zh) * | 2010-03-12 | 2011-09-21 | 陈郁 | 一种金属配合物、其制备方法及其应用 |
EP2425866A1 (en) * | 2010-08-04 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Multifunctional coating with antimicrobial activity and cell adhesion regulating surface characteristics as well as a method for preparing the same |
CN104587534A (zh) * | 2013-10-31 | 2015-05-06 | 先健科技(深圳)有限公司 | 可吸收铁基合金支架 |
CN103948458A (zh) * | 2014-05-05 | 2014-07-30 | 加奇生物科技(上海)有限公司 | 颅内药物洗脱支架 |
CN104212998B (zh) | 2014-08-21 | 2017-02-01 | 北京大学 | 一种Zn‑Mg系锌合金及其制备方法与应用 |
CN104689369B (zh) * | 2015-03-13 | 2017-06-30 | 西安爱德万思医疗科技有限公司 | 一种人体可降解的耐蚀高强韧Zn‐Fe 系锌合金及其应用 |
CN105648272A (zh) | 2016-02-01 | 2016-06-08 | 中国科学院宁波材料技术与工程研究所 | 一种可降解的锌合金材料及其制备方法和应用 |
-
2016
- 2016-01-08 CN CN201610016894.2A patent/CN106955374B/zh active Active
- 2016-06-27 EP EP16883063.6A patent/EP3400969B1/en active Active
- 2016-06-27 WO PCT/CN2016/087291 patent/WO2017117922A1/zh active Application Filing
- 2016-06-27 US US16/068,122 patent/US10799612B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017117922A1 (zh) | 2017-07-13 |
US20190008996A1 (en) | 2019-01-10 |
EP3400969A1 (en) | 2018-11-14 |
CN106955374A (zh) | 2017-07-18 |
US10799612B2 (en) | 2020-10-13 |
EP3400969B1 (en) | 2021-05-19 |
EP3400969A4 (en) | 2019-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106955374B (zh) | 植入式器械 | |
CN109010930A (zh) | 一种可吸收铁基合金支架 | |
US20060246107A1 (en) | Use of one or more elements from the group containing yttrium, neodymium and zirconium and pharmaceutical compositions containing said elements | |
CN106474545A (zh) | 可吸收铁基合金植入医疗器械 | |
Janjic et al. | Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning | |
US20090148496A1 (en) | Implants with membrane diffusion-controlled release of active ingredient | |
Hou et al. | The increased ratio of Mg2+/Ca2+ from degrading magnesium alloys directs macrophage fate for functionalized growth of endothelial cells | |
CN105597163B (zh) | 铁基合金植入医疗器械及其制备方法 | |
JP2004173770A (ja) | 体内埋込医療器具 | |
CN101091806A (zh) | 冠脉支架可降解药物缓释涂层 | |
Kim et al. | Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells | |
JP2014531933A (ja) | 介入医療機器およびその製造方法 | |
Wang et al. | In vitro and in vivo assessment of the biocompatibility of an paclitaxel-eluting poly-l-lactide-coated Mg-Zn-Y-Nd alloy stent in the intestine | |
Zhang et al. | A potential strategy for in-stent restenosis: Inhibition of migration and proliferation of vascular smooth muscle cells by Cu ion | |
Wang et al. | Rapamycin-loaded nanocoating to specially modulate smooth muscle cells on ZE21B alloy for vascular stent application | |
JP2008253707A (ja) | 薬剤溶出ステント | |
KR101328660B1 (ko) | 항암제 소라페닙을 담지한 폴리카프로락톤 고분자담지체 및 이를 이용한 약물조절 방출형 스텐트 | |
CN109954172A (zh) | 可吸收铁基植入式器械 | |
CN209864755U (zh) | 一种具有复合结构的可降解金属输尿管支架 | |
CN105797220A (zh) | 可降解铁基合金支架 | |
Chen et al. | Curcumin attenuates inflammation of Macrophage-derived foam cells treated with Poly-L-lactic acid degradation via PPARγ signaling pathway | |
CN106620897A (zh) | 一种抗再狭窄的管腔内支架材料 | |
CN105025946B (zh) | 包含大环三烯内酯药物和最少抗氧化稳定剂的可植入医疗装置及制造方法 | |
CN106902395A (zh) | 可吸收铁基合金植入医疗器械 | |
Chen et al. | Parylene-encapsulated copolymeric membranes as localized and sustained drug delivery platforms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210209 Address after: 518000 4th floor, building 4, Jinxiu Science Park, Wuhe Avenue, Longhua District, Shenzhen City, Guangdong Province Patentee after: Yuanxin Science and Technology (Shenzhen) Co.,Ltd. Address before: 518000 1st-5th Floor of Saiba Research Building, Langshan Second Road, North District of Nanshan High-tech Industrial Park, Shenzhen City, Guangdong Province Patentee before: Lifetech Scientific (Shenzhen) Co.,Ltd. |